RxDoctor Payments Data

Richard Staudacher, MD

Interventional Cardiology · Milwaukee, WINPI 1851360275

Payments from drug & device makers

$950in general payments, 2019–2025

Across 48 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$171
  • Abbott$148
  • Amgen$87
  • Lexicon Pharmaceuticals, Inc.$63
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$60
  • AstraZeneca$59
  • plus $363 from 15 others

What the payments were for

  • Food & beverage$950100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$950 in reported general payments places this provider in the 20th percentile of 118 interventional cardiology providers in Wisconsin.

See all interventional cardiology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$90,501
Medicare patients
662
Services billed
1,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban260$297,928
EntrestoSacubitril/Valsartan156$218,900
XareltoRivaroxaban102$101,969
JardianceEmpagliflozin53$60,009
Repatha SureclickEvolocumab43$56,382
BrilintaTicagrelor37$36,478
Metoprolol Succinate392$5,101
Atorvastatin Calcium448$3,569
Dabigatran EtexilateDabigatran Etexilate Mesylate11$2,401
Amiodarone Hcl28$2,132
ClopidogrelClopidogrel Bisulfate164$1,617
Rosuvastatin Calcium123$1,406
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$1,082
Losartan Potassium119$1,042
Carvedilol115$1,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$297,928260 claims
NovartisEntresto$171$218,900156 claims
Johnson & JohnsonXarelto$41$101,969102 claims
Boehringer IngelheimJardiance$14$60,00953 claims
AstraZenecaBrilinta$59$36,47837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 118 interventional cardiology providers in Wisconsin.

Other interventional cardiology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →